Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

NCT00945477 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment

Conditions

Prostate Cancer

Interventions

DRUG: Pazopanib (GW786034)

Sponsor

Illinois CancerCare, P.C.